p53 antibody (FITC)

Catalog No. ABIN94449

Product Details anti-p53 Antibody (FITC)

Target: p53 (TP53) (Tumor Protein P53 (TP53))

Reactivity: Human, Non-Human Primate

Host: Mouse

Clonality: Monoclonal

Conjugate: This p53 antibody is conjugated to FITC

Application: Flow Cytometry (FACS)

Specificity: The antibody BP53-12 recognizes a defined epitope (aa 16-25) on human p53, a 50 kDa intracellular tumour suppressor found in increased amounts in a wide variety of transformed cells, it is frequently mutated or inactivated in many types of cancer.

Cross-Reactivity (Details): Human, Non-Human Primates

Purification: Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogen: Bacterially expressed full-length wild-type p53

Clone: BP53-12

Isotype: IgG2a

Application Details

Application Notes: Flow cytometry: Recommended dilution: 3 μg/mL. Intracellular staining.

Comment:

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.
Avoid prolonged exposure to light.

Storage: 4 °C

Storage Comment: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

References for anti-p53 antibody (FITC) (ABIN94449)

Dolezalová, Vojt?sek, Kovarík: "Epitope analysis of the human p53 tumour suppressor protein." in: Folia biologica, Vol. 43, Issue 1, pp. 49-51, (1997) (PubMed).

Bártek, Bártková, Vojt?sek, Stasková, Lukás, Rejthar, Kovarík, Midgley, Gannon, Lane: "Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies." in: Oncogene, Vol. 6, Issue 9, pp. 1699-703, (1991) (PubMed).

Bártková, Bártek, Lukás, Vojt?sek, Stasková, Rejthar, Kovarík, Midgley, Lane: "p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia." in: International journal of cancer. Journal international du cancer, Vol. 49, Issue 2, pp. 196-202, (1991) (PubMed).

Target Details for p53

Target: p53 (TP53) (Tumor Protein P53 (TP53))

Alternative Name: p53 (TP53 Products)

Background: Tumor protein p53,The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.,BCC7, TRP53, TP53, LFS1

Gene ID: 7157

UniProt: P04637

Pathways: p53 Signaling, MAPK Signaling, PI3K-Akt Signaling, Apoptosis, AMPK Signaling, Chromatin Binding, ER-Nucleus Signaling, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Autophagy, Warburg Effect